Yarrow Bioscience, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The following documents are filed, or furnished as applicable, as part of this Quarterly Report on Form 10-Q:
Exhibit Index
| Exhibit Number · Incorporated by Reference · Filed | |||||
|---|---|---|---|---|---|
| Exhibit Description · Form · Date · Number · Herewith | |||||
| 2.1† | Agreement and Plan of Merger and Reorganization, dated as of December 17, 2025, by and among VYNE Therapeutics Inc., Yarrow Bioscience, Inc., and Yellow Merger Sub Corp. | 8-K | 12/17/2025 | 2.1 | |
| 2.2 | Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated as of January 30, 2026, by and among VYNE Therapeutics Inc., Yarrow Bioscience, Inc., and Yellow Merger Sub Corp. | 8-K | 1/30/2026 | 10.1 | |
| 3.1(a) | Amended and Restated Certificate of Incorporation of Yarrow Bioscience, Inc | 8-K | 7/28/2026 | 3.1(a) | |
| 3.1(b) | Certificate of Designation of Preferences, Rights, and Limitations of Series A Convertible Preferred Stock. | 10-Q | 11/14/2022 | 3.1(b) | |
| 3.1(c) | Certificate of Elimination | 8-K | 1/17/2023 | 3.1 | |
| 3.1(d) | Certificate of Amendment to the Amended and Restated Certificate of Incorporation. | 8-K | 2/10/2023 | 3.1 | |
| 3.2 | Amended and Restated Bylaws of Yarrow Bioscience, Inc. | 8-K | 7/28/2026 | 3.5 | |
| 4.1 | Form of Pre-Funded Warrant | 8-K | 7/28/2026 | 4.1 | |
| 10.1 | Employment Agreement between Tyler Zeronda and Yarrow Bioscience, Inc. | 10-Q | 5/15/2026 | 10.1 | |
| 10.2 | Yarrow Bioscience, Inc. 2026 Stock Incentive Plan. | 8-K | 7/28/2026 | 10.5 | |
| 10.3 | Yarrow Bioscience, Inc. 2026 Employee Stock Purchase Plan. | 8-K | 7/28/2026 | 10.6 | |
| 10.4 | Exclusive License Agreement, dated as of December 15, 2025, by and among Shanghai Scizeng Medical Technology Co., Ltd., Yarrow Bioscience, Inc, and the other parties thereto. | S-4 | 3/31/2026 | 10.6 | |
| 31.1 | Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1* | Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.2* | Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X |
| 101.SCH | XBRL Taxonomy Extension Schema Document with Embedded Linkbase Documents. | X |
| 104 | The cover page of Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, formatted in Inline XBRL (included within Exhibit 101 attachments). | X |
†Schedules and exhibits to the Merger Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.
- The certifications attached as Exhibit 32.1 and Exhibit 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Yarrow Bioscience, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.